Abstract

The wake-active orexin system plays a central role in the dynamic regulation of glucose homeostasis. Here we show orexin receptor type 1 and 2 are predominantly expressed in dorsal raphe nucleus-dorsal and -ventral, respectively. Serotonergic neurons in ventral median raphe nucleus and raphe pallidus selectively express orexin receptor type 1. Inactivation of orexin receptor type 1 in serotonin transporter-expressing cells of mice reduced insulin sensitivity in diet-induced obesity, mainly by decreasing glucose utilization in brown adipose tissue and skeletal muscle. Selective inactivation of orexin receptor type 2 improved glucose tolerance and insulin sensitivity in obese mice, mainly through a decrease in hepatic gluconeogenesis. Optogenetic activation of orexin neurons in lateral hypothalamus or orexinergic fibers innervating raphe pallidus impaired or improved glucose tolerance, respectively. Collectively, the present study assigns orexin signaling in serotonergic neurons critical, yet differential orexin receptor type 1- and 2-dependent functions in the regulation of systemic glucose homeostasis.

The wake-active orexin system plays a central role in the dynamic regulation of glucose homeostasis. Here the authors report that inactivation of the orexin receptor type 1 or 2 in serotonergic neurons differentially regulate systemic glucose homeostasis in the context of diet induced obesity.

Details

Title
Orexin receptors 1 and 2 in serotonergic neurons differentially regulate peripheral glucose metabolism in obesity
Author
Xiao Xing 1   VIAFID ORCID Logo  ; Yeghiazaryan Gagik 2 ; Hess, Simon 2 ; Klemm, Paul 1   VIAFID ORCID Logo  ; Sieben, Anna 1   VIAFID ORCID Logo  ; Kleinridders André 3 ; Morgan, Donald A 4 ; Thomas, Wunderlich F 1   VIAFID ORCID Logo  ; Rahmouni Kamal 4 ; Kong, Dong 5   VIAFID ORCID Logo  ; Scammell, Thomas E 6 ; Lowell, Bradford B 7 ; Kloppenburg, Peter 2 ; Brüning, Jens C 8   VIAFID ORCID Logo  ; Christine, Hausen A 1   VIAFID ORCID Logo 

 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Biocenter, Institute for Zoology, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); National Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.6190.e); University of Potsdam, Institute of Nutritional Science, Department of Molecular and Experimental Nutritional Medicine, Nuthetal, Germany (GRID:grid.11348.3f) (ISNI:0000 0001 0942 1117) 
 University of Iowa, Carver College of Medicine, Department of Neuroscience and Pharmacology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294) 
 Boston Children’s Hospital and Harvard Medical School, Division of Endocrinology, Department of Pediatrics, F.M. Kirby Neurobiology Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547) 
 Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547) 
 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547) 
 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); National Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.6190.e) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2568394169
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.